Pharmaceutical equipment is one of the basic facilities of pharmaceutical enterprises, mainly including API equipment, preparation equipment, tablet machinery, drug testing equipment, drug crushing equipment, drug packaging machinery, pharmaceutical water equipment, etc
.
In recent years, China's pharmaceutical market has shown a rapid growth trend, the growing market has attracted many competitors, many of which foreign pharmaceutical equipment giants have also increased their sales efforts and investment scale in the Chinese market, and with the advantages of capital, technology, talent, equipment, research and development and other aspects occupy the main market share
of domestic high-end pharmaceutical equipment.
China's pharmaceutical machinery enterprises are accelerating their competitiveness through a variety of ways! (Image source: Pharmaceutical Network)
However, at the same time, after years of development, China's pharmaceutical equipment industry with continuous innovation investment, has gradually formed a number of pharmaceutical equipment manufacturers with strong research and development capabilities, independent intellectual property rights, and strong competitiveness in the high-end market, such as Chutian Technology, Dongfulong, etc
.
Among them, it is worth mentioning that since 2020, representative enterprises in the pharmaceutical equipment industry have also accelerated their competitiveness
by acquiring companies, expanding their business and investing in pharmaceutical equipment production base projects through capital increase subsidiaries.
For example, Dongfulong recently issued a prospectus for the issuance of A-shares to specific targets in 2022
.
According to the announcement, the total amount of funds raised by the issuance of shares to specific targets does not exceed 3.
2 billion yuan (including this number), which is intended to be used to invest in the biopharmaceutical equipment industry trial production center project, the Jiangsu biomedical equipment industrialization base project, the Zhejiang Dongfulong Biotechnology Co.
, Ltd.
life science industrialization base project and supplementary working capital
.
On July 10, Chutian Technology announced that the company intends to issue shares to purchase a total of 49% of the shares
held by Ye Dajin and Ye Tiantian, minority shareholders of Chutian Feiyun Pharmaceutical Equipment (Changsha) Co.
, Ltd.
, a subsidiary of the company.
It is reported that after the completion of this transaction, Chutian Feiyun will become a wholly-owned subsidiary of Chutian Technology, enhancing the control of Chutian Feiyun, which will be more convenient for the company to implement the layout
in the field of solid preparation production solutions.
In addition, in April, Canaan Technology also announced that it intends to invest 50 million yuan in its own funds to establish a wholly-owned subsidiary, Tianjin Canaan Biomedical Equipment Co.
, Ltd.
(hereinafter referred to as "Tianjin Canaan").
The announcement shows that this foreign investment is an important part of the company's extension of the biopharmaceutical equipment industry chain, which is conducive to the horizontal expansion of the company's biological pharmaceutical equipment and enhances the company's market competitiveness and sustained profitability; And it is of great strategic significance
to improve and strengthen the layout of biological drug equipment.
From the overall point of view, with the continuous strengthening of research and development strength and product innovation ability, the gap between domestic pharmaceutical equipment head enterprises and international pharmaceutical equipment giants in technology and products has gradually decreased, and some products have been able to completely replace imports, and the market share in the field of high-end pharmaceutical equipment has been continuously improved
.
For example, Tailin Biology recently released the investor relations activity record table, when interviewed by the institution, it said that the company's similar products have fewer domestic competitors, and the product prices and after-sales service capabilities of foreign competitors are basically not competitive compared with the company, so the company has a strong competitive advantage
in microbial testing and sterilization equipment and other products.
The analysis believes that the current environment of the entire pharmaceutical equipment industry, including market demand, policies and other factors, as well as the rise of the tide of innovation, are bringing a new round of opportunities
to head enterprises 。 However, it should be noted that due to the low degree of production scale and intensification of China's pharmaceutical equipment industry, most small and medium-sized enterprises have weak technological development and innovation capabilities, and technical differences are large; Therefore, industry insiders also proposed that with the increasingly fierce competition in the industry and the intensification of integration, it is expected that in the next five to ten years, China's pharmaceutical equipment industry or will accelerate the formation of a small number of strong enterprises to dominate the market competition pattern, head enterprises rely on the scale, quality, technology, research and development advantages of the accumulation, will continue to increase in the high-end pharmaceutical equipment market share; A large number of small and medium-sized enterprises will face the crisis
of accelerated elimination.
